AMD3100 induces disruption of MM migration and adhesion to fibronectin and BMSCs. MM.1S cells pretreated for 2 hours with AMD3100 (50 μM), bortezomib (2.5-5 nM), or their combination. MM.1S cells were used for adhesion to fibronectin (A), adhesion to BMSC (B), or migration (C) assays. AMD3100 induced 50% inhibition of adhesion to both fibronectin and BMSCs. Bortezomib induced a dose-dependent reduction of adhesion, when at concentration of 5 nM it induced 40% and 60% inhibition of adhesion to fibronectin and BMSCs, respectively, compared with control. The combination of AMD3100 and bortezomib did not show an additive effect compared with the effect of AMD3100 alone. In transwell migration assay of MM.1S cells to 30 nM SDF1, AMD3100 inhibited migration by greater than 60% of control. Bortezomib had a mild dose-dependent effect on migration of MM.1S cells, with 5 nM inhibiting migration by 20% compared with control. The combination of AMD3100 and bortezomib showed significant reduction of migration, specifically the combination of AMD3100 and 5 nM bortezomib showed 75% reduction of migration compared with control. *P = .001; **P = .015; ***P = .005; #P = .003; ##P < .001. Error bars represent SD.